Drug Trials News http://www.mdlinx.com/pharmacy/news.cfm/newspage/1/spec_id/24/subspec_id/273 Drug Trials en-us Copyright 2013 MDLinx, Inc. <![CDATA[Results from phase III studies of naloxegol for treatment of opioid-induced constipation presented at digestive disease week 2013]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636246/?xml 5/22/2013 AstraZeneca]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636246/?xml <![CDATA[Boston scientific long term data demonstrate bronchial thermoplasty treatment benefits persist out to five years in patients with severe asthma]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636405/?xml 5/22/2013 Boston Scientific]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636405/?xml <![CDATA[New data reinforces strength of novartis once-daily copd portfolio in improving lung function, shortness of breath and reducing rate of exacerbations]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636242/?xml 5/22/2013 Novartis]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636242/?xml <![CDATA[German federal joint committee (g-ba) issues final assessment report for pixuvri (pixantrone)]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636241/?xml 5/22/2013 Cell Therapeutics]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636241/?xml <![CDATA[Asco 2013: new phase III data reveal targeted treatment with afatinib or with nintedanib improves progression-free survival in patients with advanced NSCLC]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636797/?xml 5/22/2013 Boehringer Ingelheim]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636797/?xml <![CDATA[Phase III results: tiotropium respimat effective in symptomatic asthma patients despite at least ics/laba independent of their age, allergic status, smoking status and bronchodilator response]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636794/?xml 5/22/2013 Boehringer Ingelheim]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636794/?xml <![CDATA[Asco 2013: Boehringer Ingelheim to present highly anticipated new phase iii results for front-runner compounds afatinib and nintedanib in first- and second-line nsclc treatment]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636796/?xml 5/22/2013 Boehringer Ingelheim]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636796/?xml <![CDATA[Sanofi and regeneron announce publication of positive phase 2a results of dupilumab in asthma in the new England journal of medicine]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636801/?xml 5/22/2013 Sanofi]]> http://www.mdlinx.com/pharmacy/news-article.cfm/4636801/?xml